Early use of an anti-inflammatory agent to improve prognosis in Covid-19 patients |
Editorial
eMediNexus Coverage from: 
Early use of an anti-inflammatory agent to improve prognosis in Covid-19 patients

6 Read Comments                

The hallmark of Covid-19 is a hyperinflammatory response characterised by raised inflammatory markers (C-reactive protein, ferritin and D-dimers) and inflammatory cytokines and increased neutrophil-to-lymphocyte ratio. And, if this inflammatory response continues unabated, it can even be life-threatening. Hence, controlling this inflammatory response is key to improving prognosis.Hospitalized covid-19 patients have a more aggressive inflammatory response than patients being treated at home. The cytokine storm has been majorly implicated in severity of disease resulting in acute respiratory distress (ARDS), pulmonary edema and multi-organ failure. Early intervention with an anti-inflammatory drug to suppress this inflammatory response, particularly in non-hospitalized patients, may prevent lung damage by controlling the cytokine storm thereby reducing the need for hospital admission. ...
To Read or comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now